Hung Trinh/LinkedIn
Jun 15, 2025, 14:48
Hung Trinh: BioNTech and Bristol Myers Squibb Partner on $11.1 Billion Cancer Immunotherapy Deal
Hung Trinh, Senior Director of Business Development at OBiO Tech and Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“Bristol Myers Squibb agrees up to $11.1 billion deal with BioNTech SE to shake up cancer immunotherapy – Reuters
Bristol Myers, BioNTech team up on experimental cancer drug
Deal could eventually exceed $11 billion for BioNTech
BioNTech shares surge on the newsJune 2 (Reuters) – Bristol Myers Squibb (BMY.N), opens new tab has agreed to pay up to $11.1 billion to partner with Germany’s BioNTech and develop the latter’s next-generation cancer immunotherapy, which could take on rival Merck & Co’s best-selling drug Keytruda.
The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech’s ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer’s COVID-19 vaccine partner was not a one-off achievement.
It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system – similar to an established drug class including Merck & Co’s (MRK.N), opens new tab Keytruda – but which also cuts a tumour’s blood supply.
BioNTech’s German-listed shares (22UAy.DE), opens new tab surged 16.7% by 1236 GMT to a six-week high.
The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech’s drug, BNT327, for multiple solid tumour types.”
More posts featuring Hung Trinh.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 15, 2025, 14:09